OSUR logo

ORASURE TECHNOLOGIES INC

OSURNASDAQ
πŸ† #3498 by market capEarnings Nov 3US Equity
$598.48β–Ό $23.10 (βˆ’3.86%)
Simulated price
πŸ””
Track OSUR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.9%
7dβ–² 14824.7%
14dβ–² 17048.4%
30dβ–² 16617.3%
ytdβ–² 24630.6%
1yβ–² 18544.2%
🏦Market Cap
$265M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-38.1%
Declining
πŸ“ŠGross Margin
41.4%
Healthy
πŸ’΅FCF Margin
-42.8%
Thin
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$595.44 – $604.02
52-Week Range
$2.08 – $4.58
Volume
$2.12B
Avg Volume
$2.71B
Shares Outstanding
68.8M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$115M
Last Q Revenue
$31M
P/E Ratio
-5.6
P/S Ratio
2.4x
EPS (TTM)
$-0.71
Dividend Yield
0.00%
Dilution (1yr)
βˆ’3.9%

Why Investors Own OSUR

  • βœ“High-growth profile β€” revenue up +11.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 28% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OSUR logo

ORASURE TECHNOLOGIES INC

OSUR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$115Mβ–Ό βˆ’38.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
41.9%β–² +2.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$68Mβ–² +230.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$53Kβ–Ό βˆ’100.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
71.6Mβ–Ό βˆ’3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$186Mβ–Ό βˆ’$67M YoY
StockOtter Β· stockotter.space

About ORASURE TECHNOLOGIES INC

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
56/100

Analyst Price Target

β“˜
Average Target
$670.53
β–² +12.0% Upside
High Target$733.92
Low Target$540.10
Based on 24 analysts

Latest News & Updates